📊 HRGN Key Takeaways
Is HRGN a Good Investment? Thesis Analysis
This development-stage medical device company demonstrates promising revenue growth (+63.7% YoY) but faces critical financial distress with zero gross margins, operating losses of -$6.9M on only $704K revenue, and negative operating cash flow of -$3.8M. At the current burn rate, existing cash reserves of $1.4M provide less than 5 months of operational runway, creating severe existential risk without immediate revenue acceleration or external funding.
Why Buy HRGN? Key Strengths
- Revenue growth of 63.7% YoY demonstrates market demand for products/services
- No long-term debt burden provides balance sheet flexibility
- Positive cash position of $1.4M provides near-term operational cushion
HRGN Investment Risks to Consider
- Zero gross profit margin indicates business model is not generating positive unit economics
- Operating cash burn of -$3.8M annually with estimated 4-5 month cash runway creates imminent liquidity crisis
- Operating expenses of $6.9M exceed revenue by 976%, with no clear path to profitability visible
- Negative free cash flow and inability to self-fund operations requires external capital dependency
- Pre-commercial or early-stage business model with unproven ability to scale profitably
Key Metrics to Watch
- Gross profit margin progression toward breakeven
- Monthly cash burn rate and updated runway assessment
- Revenue growth sustainability and acceleration trajectory
- Operating expense reduction initiatives and efficiency gains
- Funding announcements or capital raises for runway extension
HRGN Financial Metrics
💡 AI Analyst Insight
Harvard Apparatus Regenerative Technology, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
HRGN Profitability Ratios
HRGN vs Healthcare Sector
How Harvard Apparatus Regenerative Technology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HRGN Overvalued or Undervalued?
Based on fundamental analysis, Harvard Apparatus Regenerative Technology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HRGN Balance Sheet & Liquidity
HRGN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Harvard Apparatus Regenerative Technology, Inc.'s revenue has grown significantly by 583% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.55 indicates the company is currently unprofitable.
HRGN Growth Metrics (YoY)
HRGN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $59.0K | -$1.7M | N/A |
| Q2 2025 | $56.0K | -$1.8M | N/A |
| Q1 2025 | $45.0K | -$1.7M | N/A |
| Q3 2024 | $40.0K | -$1.6M | $-0.12 |
| Q2 2024 | $56.0K | -$2.5M | $-0.18 |
| Q1 2024 | $57.0K | -$2.0M | $-0.15 |
| Q3 2023 | $40.0K | -$1.1M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HRGN Capital Allocation
HRGN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Harvard Apparatus Regenerative Technology, Inc. (CIK: 0001563665)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HRGN
What is the AI rating for HRGN?
Harvard Apparatus Regenerative Technology, Inc. (HRGN) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HRGN's key strengths?
Claude: Revenue growth of 63.7% YoY demonstrates market demand for products/services. No long-term debt burden provides balance sheet flexibility.
What are the risks of investing in HRGN?
Claude: Zero gross profit margin indicates business model is not generating positive unit economics. Operating cash burn of -$3.8M annually with estimated 4-5 month cash runway creates imminent liquidity crisis.
What is HRGN's revenue and growth?
Harvard Apparatus Regenerative Technology, Inc. reported revenue of $704.0K.
Does HRGN pay dividends?
Harvard Apparatus Regenerative Technology, Inc. does not currently pay dividends.
Where can I find HRGN SEC filings?
Official SEC filings for Harvard Apparatus Regenerative Technology, Inc. (CIK: 0001563665) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HRGN's EPS?
Harvard Apparatus Regenerative Technology, Inc. has a diluted EPS of $-0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HRGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Harvard Apparatus Regenerative Technology, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HRGN stock overvalued or undervalued?
Valuation metrics for HRGN: ROE of -649.9% (sector avg: 15%), net margin of -975.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HRGN stock in 2026?
Our dual AI analysis gives Harvard Apparatus Regenerative Technology, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HRGN's free cash flow?
Harvard Apparatus Regenerative Technology, Inc.'s operating cash flow is $-3.8M, with capital expenditures of $0.0. FCF margin is -543.8%.
How does HRGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -975.7% (avg: 12%), ROE -649.9% (avg: 15%), current ratio 1.19 (avg: 2).